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Abstract
Background: There is ample literature available on the association between both time to antibiotics and appropriateness of
antibiotics and clinical outcomes from sepsis. In fact, the current state of debate surrounds the balance to be struck
between prompt empirical therapy and care in the choice of appropriate antibiotics (both in terms of the susceptibility of
infecting organism and minimizing resistance arising from use of broad-spectrum agents). The objective of this study is to
determine sepsis bundle compliance and the appropriateness of antimicrobial therapy in patients with severe sepsis and
septic shock and its impact on outcomes.
Material: This study was conducted in the ICU of a tertiary care, private hospital in Sa˜o Paulo, Brazil. A retrospective cohort
study was conducted from July 2005 to December 2012 in patients with severe sepsis and septic shock.
Results: A total of 1,279 patients were identified with severe sepsis and septic shock, of which 358 (32.1%) had bloodstream
infection (BSI). The inpatient mortality rate was 29%. In evaluation of the sepsis bundle, over time there was a progressive
increase in serum arterial lactate collection, obtaining blood cultures prior to antibiotic administration, administration of
broad-spectrum antibiotics within 1 hour, and administration of appropriate antimicrobials, with statistically significant
differences in the later years of the study. We also observed a significant decrease in mortality. In patients with bloodstream
infection, after adjustment for other covariates the administration of appropriate antimicrobial therapy was associated with
a decrease in mortality in patients with severe sepsis and septic shock (p = 0.023).
Conclusions: The administration of appropriate antimicrobial therapy was independently associated with a decline in
mortality in patients with severe sepsis and septic shock due to bloodstream infection. As protocol adherence increased
over time, the crude mortality rate decreased, which reinforces the need to implement institutional guidelines and monitor
appropriate antimicrobial therapy compliance.
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Background
Severe sepsis and septic shock are worrisome manifestations of
systemic infection and the leading causes of hospitalization in
intensive care units (ICUs), where an estimated 19 million cases
occur worldwide each year, resulting in the death of one in four of
these patients [1,2]. According to the Ministry of Health of Brazil,
severe sepsis and septic shock are responsible for an average of
41% of the total yearly in-hospital mortality for adults from 2008
through August 2013. Case mortality is 46% in the southeast
region [3], which reinforced our desire to participate in the
Surviving Sepsis Campaign beginning in 2004, as well as the ‘‘Stop
Sepsis, Save Lives’’ project [4,5].
According to the international guidelines, for the immediate
treatment of severe sepsis or septic shock, antibiotic administration
should occur within the first hour of recognition as it directly
impacts in mortality [2]. Since 2006, we have utilized the sepsis
bundle in our ICU [6], the treatment recommendations were
organized in two bundles: a resuscitation bundle (6 tasks to begin
immediately and to be accomplished within 6 hours) and a
management bundle (4 tasks to be completed within 24 hours) [4];
however, there is no evaluation of the appropriateness of
antimicrobial therapy after collecting blood cultures in sepsis
bundle studies, which is one of the main measures to reduce
mortality in critically ill patients suffering from infectious
processes. When longer time frames to appropriate antibiotic
therapy are observed there is an increased risk of death [7–9].
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Thus, the objectives of the study were to determine i) the sepsis
bundle compliance, ii) as well as the appropriateness of antimi-
crobial therapy for patients with severe sepsis and septic shock, as
well as impact on outcomes.
Methods
This study was conducted in the ICU of a tertiary care, private
hospital in Sa˜o Paulo, Brazil. This open model ICU is a 41-bed
medical-surgical unit with approximately 10,500 patient-days
yearly.
A retrospective cohort study was conducted from July 2005 to
December 2012 in patients with severe sepsis and septic shock to
analyze the impact of appropriate antimicrobial therapy. This
study was a quality improvement project that was approved by the
Institutional Review Board (IRB) of Hospital Israelita Albert
Einstein. The requirements for informed consent were waived by
our IRB in accordance of the Code of Federal Regulation and of
the Privacy Rule. This project includes data from our previous
sepsis bundle study from July 2005 to December 2009 [6] with the
addition of observations for the period from January 2010 to
December 2012 in order to evaluate whether sustained imple-
mentation of the sepsis bundle in our ICU could effectively reduce
mortality in severe sepsis and septic shock patients.
Sepsis was defined as infection plus two or more of the following
SIRS criteria: T.38uC or ,36uC; heart rate .90/min;
respiratory rate .20 breaths/min (or Paco2,32 mm Hg); or
WBC count, .12,000 cells/mL or ,4,000 cells/mL (or .10%
band forms) [10]. Severe sepsis was defined as sepsis plus organ
dysfunction, hypotension, or hypoperfusion abnormalities, includ-
ing lactic acidosis, oliguria, or encephalopathy. Septic shock was
defined as sepsis-induced hypotension (ie, systolic BP, ,90 mm
Hg or a drop of .40 mm Hg in the absence of other cause of
hypotension) plus hypoperfusion abnormalities despite adequate
fluid resuscitation [10] (Appendix S1) Infection was defined
according to the definitions of the International Sepsis Forum
[11] and adjudicated by the patient’s physician.
The data collected included age, gender, admission date, the
time when severe sepsis or septic shock was diagnosed, location
before ICU admission, hospital and ICU length of stay, organ
dysfunction at the time of diagnosis, APACHE II score on
admission, and outcome status (death was defined as in-hospital
mortality). As per the Surviving Sepsis Campaign, ‘‘time zero’’ was
defined as the time of diagnosis of severe sepsis or septic shock.
Once a patient meets the bundle initiation criteria, the 6-hour
bundle was initiated by collecting serum arterial lactate and
obtaining blood cultures before antibiotic administration (Appen-
dix S1). From the time of severe sepsis (time zero), broad-spectrum
antibiotics are to be administered within 1 hour (since every hour
of delay increases the risk of poorer outcomes). Hypotension and/
or elevated lactate are treated with IV fluids; in the event of
persistent hypotension despite fluid resuscitation (septic shock)
and/or lactate .4 mmol/L (.36 mg/dL), maintaining adequate
central venous pressure and central venous oxygen saturation are
indicated. Patients who do not have septic shock and elevated
lactate .4 mmol/L (.36 mg/dL) do not require measurement of
central venous pressure and central venous oxygen saturation.
The first 24-hour management bundle includes optimization of
glycemic control, respiratory inspiratory plateau pressure, and
determination of the need for corticosteroids and drotrecogin alfa
(activated) [4]. However, we did not perform analysis for the 24-
hour sepsis bundle for patients with severe sepsis or septic shock
because there have been changes in the recommendations (e.g.,
glycemic control, and use of activated protein C) [2,6].
Our hospital has an electronic system for activating a team
dedicated to diagnosing and treating severe sepsis and septic shock
patients immediately. The ICU doctor and the nurse manager are
simultaneously notified. The development of this sepsis team was
part of implementing the sepsis bundle. Our hospital also has had
a rapid response team since 2007 [6]. The rapid response team is
alerted based on the following criteria: respiratory problems such
as acute decrease in oxygen saturation ,90% and change in
respiratory rate to ,8/minute or .28/minute; circulatory
problems: decrease in systolic arterial pressure to ,90 mmHg
associated with symptoms; and change in heart rate to ,40 bpm
or .130 bpm; neurologic problems: decreasing consciousness
levels or seizures; or a serious concern with the patient’s overall
condition (patient claims to be feeling unwell or has the sensation
‘‘something is not right’’), and change in color, diaphoresis, or
coolness of the extremities. Some of these described signs are the
same as those noted in sepsis patients [6,12].
Antimicrobial therapy
Antimicrobial therapy was considered appropriate if the
bacteria identified in blood culture was susceptible to at least
one of the antibiotics administered within 24 hours after the
collection of culture. If the isolated microorganism was not
susceptible by in vitro testing to the antibiotic used, the therapy
was considered inadequate [7].
The microbiology laboratory has an alert system to notify
physicians of patients with positive blood cultures and their gram
stain results.
Microbiological methods
All samples were identified by manual or automated method
and confirmed using the Vitek 2 (bio-Merieux Vitek, Inc.,
Hazelwood, MO) system. To determine the prevalence of
antimicrobial resistance, the same organism with identical
antimicrobial profiles from the same or different anatomic sites
in the same patient were considered a single isolate. Antimicrobial
susceptibility testing was performed by an automated method or
by disk diffusion as described by the Clinical and Laboratory
Standards Institute (CLSI) [13].
Statistical analysis
Differences over time were evaluated by autoregressive time
series models. The order of the models was determined according
to the analysis of the partial autocorrelation function of residuals.
The summary of the year was presented as means 6 standard
deviations or as absolute frequencies and percentages. Significance
of changes was evaluated by trend effects. All tests of significance
are two-tailed and alpha was set at 0.05.
To analyze the impact of inadequate antimicrobial therapy on
mortality in the 358 patients with bloodstream infection, models
were constructed by binary logistic regression in single and
multiple approaches, only with data collected between 2010 and
2012. The variables with p#0.10 in the simple analysis models
were evaluated via multivariate analysis. The association of
independent variables was expressed as odds ratios with 95%
confidence intervals.
Analyses were performed with the Statistical Package for the
Social Sciences 17.0 (Chicago, IL, USA).
Results
The total cohort, shown in Figure S1, consisted of 1,279
consecutive patients, where 57.7% (N = 738) were male, mean age
6 standard deviation (SD) 67618 years, mean APACHE II score
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of 18610, mean length of stay 33671 days, mean time to
administration of antibiotic was 2.563.6 hours, mean serum
arterial lactate 27624 mg/dL, and mean 6 central venous
oxygen saturation 76.2611.4%. The total number of deaths was
371 (29.0%).
In analysis of sepsis bundle performance by year (table 1), there
was a significant progressive increase in serum arterial lactate
collection, administration of broad-spectrum antibiotic within
1 hour, and treatment with appropriate antimicrobial therapy. We
also observed a significant decrease in crude mortality (figure S2).
In our cohort, 163 patients (12.7%) did not have blood culture
collected. Of the 1,116 patients with blood cultures collected, 358
(32.1%) were positive. Comparing patients with and without
positive blood cultures, cardiac dysfunction and a high APACHE
II score were more prevalent in patients with positive blood
cultures (p-value ,0.001 and 0.005, respectively, table 2). Older
patients and those with respiratory dysfunction were more likely to
have negative blood cultures (p-value ,0.001 and 0.05, respec-
tively).
For all patients with severe sepsis and septic shock, higher
APACHE II scores were an independent predictor of mortality
(Table 3). Patients with circulatory dysfunction, renal dysfunction,
hematologic dysfunction, and respiratory dysfunction also had
increased odds of death. Mortality was significantly lower in
patients who had blood cultures obtained, and in those for whom
serum arterial lactate was measured.
In the subset of patients with bloodstream infection, the
APACHE II score were also remained an independent predictor
of death (Table 4). Patients with renal and neurological dysfunc-
tion also had increased odds of death. After adjustment for other
covariates, the administration of appropriate antimicrobial ther-
apy was associated with a decreased risk of mortality (OR 0.54,
p = 0.023) (Table 4). Higher APACHE II scores and the presence
of polymicrobial infection were associated with inadequate
antimicrobial therapy (p,0.001 and p = 0.016, respectively)
(Table 5).
Among the 358 patients with positive blood cultures, 333
(93.0%) had monobacterial infections (table 6). The most common
pathogens were Escherichia coli (n = 101, 28.2%), Streptococcus
pneumoniae (n = 31, 8.7%). Bacteria belonging to the ESKAPE
group were represented as follows: Staphylococcus aureus (n = 24,
6.7%), Klebsiella pneumoniae (n = 20, 5.6%), Pseudomonas
aeruginosa (n = 18, 5.0%), Enterobacter spp (n = 10, 2.8%),
Enterococcus faecium (n = 2, 0.6%), Acinetobacter baumannii
(n = 4, 1.1%). Considering fungal infections, 5 patients (1.5%)
had Candida bloodstream infection; of these, 2 patients had
Candida albicans, 2 patients had Candida parapsilosis, and one
patient Candida krusei. Among the monomicrobial infection cases
74.2% (n = 247) received adequate antimicrobial therapy. One
reason for inadequate therapy was fungal bloodstream infection
(83.3%, n = 5). There were few cases of polymicrobial bloodstream
infections (N = 25, 7.0%). More than a half of these cases received
adequate antimicrobial therapy (n = 13, 52.0%). Highly resistant
organisms not covered by usual empiric therapy as represented by
the ESKAPE pathogen group could be expected to be associated
with inadequate therapy; however, we were not able to
demonstrate this by the multivariate analysis (table 5).
Discussion
With improvement of compliance to the sepsis bundle over
time, we demonstrate an association with reduced mortality. Not
surprisingly, risk factors for death include the APACHE II score,
as well as the presence of other disorders that contribute to severe
worsening of the patient’s general condition [1].
In addition to implementing the sepsis protocol at our
institution (May 2006), practical bedside contact with evidence-
based medicine and attendance at several scientific meetings by
the multidisciplinary team also contributed in improving the care
of these patients. Over the period of analysis, changes in
treatment, such as the utilization of Activated protein C followed
by its suspension reflect the need for continuous learning and
improving based on the state of the science [6].
Another important fact, demonstrated by logistic regression, is
that despite the implementation of the measures incorporated in
the sepsis bundle, such as collecting serum arterial lactate and
timely administration of antibiotics, it was antimicrobial appro-
priateness that contributed to decreased mortality in severe sepsis
and septic shock patients. Over the past two years, our mortality
rate in severe sepsis and septic shock patients was below 20% as
Table 2. Comparison between patients with and without positive blood cultures.
Variables Blood culture p
Negative (N=758) Positive (N=358)
Male - n (%) 432 (57.%) 221 (61.7%) 0.134
Organ dysfunction – n (%)
Liver 39 (5.1%) 27 (7.5%) 0.113
Cardiologic 492 (64.9%) 273 (76.3%) ,0.001
Renal 286 (37.7%) 138 (38.5%) 0.793
Hematologic 277 (36.5%) 134 (37.4%) 0.774
Respiratory 529 (69.8%) 210 (58.7%) ,0.001
Neurologic 260 (34.3%) 119 (33.2%) 0.727
Metabolic acidosis on admission 252 (33.2%) 133 (37.2%) 0.200
Mortality rate – n (%) 185 (24.4%) 101 (28.2%) 0.174
Apache II - mean (±SD) 16.8 (610.1) 18.1 (610.2) 0.005
Age - mean (±SD) 67.5 (618.3) 64.2 (617.9) 0.050
163 patients without blood culture collected during the study period.
doi:10.1371/journal.pone.0104475.t002
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compared to 55% prior to the implementation of the sepsis bundle
[6].
Over time, after implementation of the bundle, we observed
improved compliance with the protocol (Figure S2); in 2012 we
had 54% compliance with the sepsis bundle, and a 17% mortality
rate. The correct antibiotics, administered at the right time,
contribute to an effective recovery of the patient. It also acts as a
measurable and actionable safety metric, which reduces mortality
by decreasing the time of exposure to the organism and its toxins.
This has been the target of study of several groups around the
world [14–17]. However, the indiscriminate use of antibiotics may
lead, for example, to the development of antimicrobial resistance
and an increase in Clostridium difficile infections. In addition,
some antimicrobials have side effects that require caution and
rational prescribing [7–9].
While empiric antibiotic therapy is important [17], targeted
therapy based on culture results should also be a goal. However,
sepsis bundle evaluation studies have not examined the appropri-
ateness of the antimicrobial therapy administered [18].
Because identification of pathogens in cultures is time intensive,
one of the ways that our institution found to speed up the process
of communicating blood cultures results was for laboratory staff to
call the physicians responsible for the patient.
Of the ESKAPE pathogens [19,20], which have paramount
importance due to the their pathogenesis, transmission mode and
antimicrobial resistance, the most common was E.coli. However,
the incidence of S. aureus (MRSA) and E. faecium (VRE) cases
was low (Table 6).
Regarding the appropriateness of antibiotic selection for the
cases with positive blood culture, our data show a fair rate of
treatment adequacy, but in relation to fungal infections of the five
cases identified 60.0% (3/5) died and none were receiving
adequate therapy (Table 6). In the APACHE II study [21],
calculations were done only on the day of admission. One
explanation to justify why patients with higher APACHE II were
associated with inadequate antimicrobial therapy was in the first
24 hours there was an underestimation of the severity of these
patients and the appropriate antimicrobial therapy. If we had
calculated the prognostic score on our patients at the time of
severe sepsis and septic shock diagnosis, the APACHE score would
likely be very different. Recently, in a similar study evaluating
etiology, antimicrobial therapy and outcome of patients with
severe sepsis, quick identification of the source of infection, proper
sampling for microbiological analyses, and the rapid administra-
tion of adequate antimicrobial therapy were shown to be crucial
management points [22].
Study Limitations
A limitation of our study is that it was performed at a single
private medical facility so it may not be generalizable to other
hospitals (e.g., public facilities). In addition, data was retrospec-
tively collected from medical records; however because of the
sepsis bundle protocol these septic patients were followed
prospectively. Lastly, we did not include microbiologic data from
sites other than blood cultures with regards to assessing
appropriateness of antimicrobial therapy. However, cultures from
nonsterile sites (e.g., respiratory tract) are more difficult to
interpret since in many cases the organisms are colonizing rather
than causing true infection.
Implications for policy and practice
Other improvements that were taking place may have impacted
our study findings. Since 2007 our hospital has been engaged in
zero tolerance for healthcare associated infections. We have
observed a significant reduction in ventilator-associated pneumo-
nia and in central venous associated bloodstream infections
[23,24]. We also implemented other ICU best practices during
the study period, including a glycemic control protocol [25]. We
adopted intermediate glucose control, because we believe that
tight glucose control is difficult to accomplish in routine intensive
care unit settings and is associated with a significant increase in the
incidence of hypoglycaemia [25,26]. However, it is interesting to
note that the best practices for the care of patients with severe
sepsis and septic shock were improving over time in our ICU. This
affirms our belief that the sepsis bundle needs to be considered as
the intervention decreasing mortality in septic shock and severe
sepsis because of the better care and the prompt recognition of
these patients in hospital [6].
Conclusions
Appropriate antimicrobial therapy and implementation of the
sepsis bundle in patients with severe sepsis and septic shock due to
bloodstream infection was associated with a 46% reduction in
mortality. Assessment of appropriate antimicrobials should be
incorporated into the Surviving Sepsis Campaign as a quality
metric [18].
Supporting Information
Figure S1 Flow-diagram - Cohort selection of total patients,
septic shock patients and bloodstream infection.
(TIF)
Figure S2 Proportion of patients with severe sepsis and septic
shock who died and sepsis bundle compliance.
(TIF)
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